Boardroom Alpha
Boardroom Alpha
AVBP · Additional Proxy Materials (DEFA14A) · Filed April 28, 2026

Arrivent Biopharma Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 28, 2026
Ticker
AVBP
Accession
0001104659-26-050344
Boardroom Alpha · Filing insights

Arrivent BioPharma's board recommends voting for all three director nominees and ratifying PwC as auditor.

About Arrivent Biopharma Inc
Market cap
$1.4B
1Y TSR
+22.8%
Board grade
C-
Sector
Healthcare
Last annual meeting: Jun 18, 2026 · View full Arrivent Biopharma Inc profile →

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 

(Amendment No.  )

 

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

 

¨Preliminary Proxy Statement
¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨Definitive Proxy Statement
xDefinitive Additional Materials
¨Soliciting Material Under §240.14a-12

 

ArriVent BioPharma, Inc.

 

(Name of Registrant as Specified In Its Charter)

 

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

xNo fee required
¨Fee paid previously with preliminary materials
¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

GRAPHIC

Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V96463-P51036 ARRIVENT BIOPHARMA, INC. 18 CAMPUS BOULEVARD SUITE 100 NEWTOWN SQUARE, PENNSYLVANIA 19073 UNITED STATES ARRIVENT BIOPHARMA, INC. 2026 Annual Meeting Vote by June 17, 2026 11:59 PM ET You invested in ARRIVENT BIOPHARMA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2026. Vote Virtually at the Meeting* June 18, 2026 12:00 p.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/AVBP2026 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

GRAPHIC

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V96464-P51036 1. Election of Directors For Nominees: 01) James Healy, M.D., Ph.D. 02) John Hohneker, M.D. 03) Stuart Lutzker, M.D., Ph.D. 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof. THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Arrivent Biopharma Inc (AVBP)

Reference

Frequently asked questions

When did Arrivent Biopharma Inc file this DEFA14A?
Arrivent Biopharma Inc (AVBP) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 28, 2026. The accession number assigned by EDGAR is 0001104659-26-050344.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Arrivent BioPharma's board recommends voting for all three director nominees and ratifying PwC as auditor. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Arrivent Biopharma Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Arrivent Biopharma Inc has filed under CIK 1868279, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer